Hybio Pharmaceutical is a Manufacturer/Innovator company operating in the pharmaceutical industry.
Hybio is a hi-tech enterprise specializing in the R&D and manufacturing of diverse peptide products. Founded in 1998, we have grown up to be a leading peptide pharmaceutical company and the first to go public in China (2011, stock code 300199). We offer a full range of peptide products (API & FDF) and services (CRO & CDMO). Our peptide FDFs are mainly sold in the Chinese domestic market, and peptide APIs are mostly supplied worldwide. Headquarters Shenzhen Nanshan has passed EU AEMPS, US FDA, Korea and China Authority inspections.
Company type
Manufacturer/Innovator
Products and services
APIs (Active Pharmaceutical Ingredients)
Markets
Oceania, North America (USA, Canada), Africa, Middle East Region (e.g. UAE), Central America (e.g. Mexico), East Asia (e.g. China, Japan, Korea), Europe – EU countries, Europe – non EU (e.g. UK, Russia, ex-CIS countries), South America (e.g. Brazil, Colombia), South Asia (e.g. India, Pakistan, Sri Lanka), South East Asia (e.g. Thailand, Philippines, Singapore)
Useful Links
Connect with Hybio Pharmaceutical on LinkedIn
Address
Hybio Pharmaceutical, No.9, Linkong West Street, Hengdian Street, Shenzhen, China,
